Prostate cancer, version 1.2014

Featured updates to the NCCN Guidelines

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D'Amico, James A. Eastham, Charles Arthur Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey & 11 others Mack Roach, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, Maria Ho

Research output: Contribution to journalReview article

70 Citations (Scopus)

Abstract

The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

Original languageEnglish (US)
Pages (from-to)1471-1479
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2013

Fingerprint

Prostatic Neoplasms
Guidelines
Radium
Radiopharmaceuticals
Androgens
Neoplasm Metastasis
Bone and Bones
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Mohler, J. L., Kantoff, P. W., Armstrong, A. J., Bahnson, R. R., Cohen, M., D'Amico, A. V., ... Ho, M. (2013). Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 11(12), 1471-1479. https://doi.org/10.6004/jnccn.2013.0174

Prostate cancer, version 1.2014 : Featured updates to the NCCN Guidelines. / Mohler, James L.; Kantoff, Philip W.; Armstrong, Andrew J.; Bahnson, Robert R.; Cohen, Michael; D'Amico, Anthony Victor; Eastham, James A.; Enke, Charles Arthur; Farrington, Thomas A.; Higano, Celestia S.; Horwitz, Eric Mark; Kawachi, Mark H.; Kuettel, Michael; Lee, Richard J.; MacVicar, Gary R.; Malcolm, Arnold W.; Miller, David; Plimack, Elizabeth R.; Pow-Sang, Julio M.; Richey, Sylvia; Roach, Mack; Rohren, Eric; Rosenfeld, Stan; Small, Eric J.; Srinivas, Sandy; Stein, Cy; Strope, Seth A.; Tward, Jonathan; Walsh, Patrick C.; Shead, Dorothy A.; Ho, Maria.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 11, No. 12, 01.12.2013, p. 1471-1479.

Research output: Contribution to journalReview article

Mohler, JL, Kantoff, PW, Armstrong, AJ, Bahnson, RR, Cohen, M, D'Amico, AV, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Kawachi, MH, Kuettel, M, Lee, RJ, MacVicar, GR, Malcolm, AW, Miller, D, Plimack, ER, Pow-Sang, JM, Richey, S, Roach, M, Rohren, E, Rosenfeld, S, Small, EJ, Srinivas, S, Stein, C, Strope, SA, Tward, J, Walsh, PC, Shead, DA & Ho, M 2013, 'Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 11, no. 12, pp. 1471-1479. https://doi.org/10.6004/jnccn.2013.0174
Mohler, James L. ; Kantoff, Philip W. ; Armstrong, Andrew J. ; Bahnson, Robert R. ; Cohen, Michael ; D'Amico, Anthony Victor ; Eastham, James A. ; Enke, Charles Arthur ; Farrington, Thomas A. ; Higano, Celestia S. ; Horwitz, Eric Mark ; Kawachi, Mark H. ; Kuettel, Michael ; Lee, Richard J. ; MacVicar, Gary R. ; Malcolm, Arnold W. ; Miller, David ; Plimack, Elizabeth R. ; Pow-Sang, Julio M. ; Richey, Sylvia ; Roach, Mack ; Rohren, Eric ; Rosenfeld, Stan ; Small, Eric J. ; Srinivas, Sandy ; Stein, Cy ; Strope, Seth A. ; Tward, Jonathan ; Walsh, Patrick C. ; Shead, Dorothy A. ; Ho, Maria. / Prostate cancer, version 1.2014 : Featured updates to the NCCN Guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2013 ; Vol. 11, No. 12. pp. 1471-1479.
@article{33a284b3d2464f7999dcc8c1a4ca1280,
title = "Prostate cancer, version 1.2014: Featured updates to the NCCN Guidelines",
abstract = "The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.",
author = "Mohler, {James L.} and Kantoff, {Philip W.} and Armstrong, {Andrew J.} and Bahnson, {Robert R.} and Michael Cohen and D'Amico, {Anthony Victor} and Eastham, {James A.} and Enke, {Charles Arthur} and Farrington, {Thomas A.} and Higano, {Celestia S.} and Horwitz, {Eric Mark} and Kawachi, {Mark H.} and Michael Kuettel and Lee, {Richard J.} and MacVicar, {Gary R.} and Malcolm, {Arnold W.} and David Miller and Plimack, {Elizabeth R.} and Pow-Sang, {Julio M.} and Sylvia Richey and Mack Roach and Eric Rohren and Stan Rosenfeld and Small, {Eric J.} and Sandy Srinivas and Cy Stein and Strope, {Seth A.} and Jonathan Tward and Walsh, {Patrick C.} and Shead, {Dorothy A.} and Maria Ho",
year = "2013",
month = "12",
day = "1",
doi = "10.6004/jnccn.2013.0174",
language = "English (US)",
volume = "11",
pages = "1471--1479",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "12",

}

TY - JOUR

T1 - Prostate cancer, version 1.2014

T2 - Featured updates to the NCCN Guidelines

AU - Mohler, James L.

AU - Kantoff, Philip W.

AU - Armstrong, Andrew J.

AU - Bahnson, Robert R.

AU - Cohen, Michael

AU - D'Amico, Anthony Victor

AU - Eastham, James A.

AU - Enke, Charles Arthur

AU - Farrington, Thomas A.

AU - Higano, Celestia S.

AU - Horwitz, Eric Mark

AU - Kawachi, Mark H.

AU - Kuettel, Michael

AU - Lee, Richard J.

AU - MacVicar, Gary R.

AU - Malcolm, Arnold W.

AU - Miller, David

AU - Plimack, Elizabeth R.

AU - Pow-Sang, Julio M.

AU - Richey, Sylvia

AU - Roach, Mack

AU - Rohren, Eric

AU - Rosenfeld, Stan

AU - Small, Eric J.

AU - Srinivas, Sandy

AU - Stein, Cy

AU - Strope, Seth A.

AU - Tward, Jonathan

AU - Walsh, Patrick C.

AU - Shead, Dorothy A.

AU - Ho, Maria

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

AB - The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

UR - http://www.scopus.com/inward/record.url?scp=84891951693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891951693&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2013.0174

DO - 10.6004/jnccn.2013.0174

M3 - Review article

VL - 11

SP - 1471

EP - 1479

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 12

ER -